Getting Under the Skin With GPP: Understanding and Treating a Rare Dermatologic Disorder - Live Webcast September 28, 2023 Pretest (ID: i879-2)

To assist us in evaluating the effectiveness of this activity, please complete the following pretest.

Question Title

* 1. Which of the following best describes your profession?

MD/DO

PharmD/RPh

Other (please specify)

Question Title

* 2. Which of the following best describes your specialty?

Dermatology

Primary Care

Other (please specify)

Question Title

* 3. How confident are you in the management of patients with GPP in your practice?

Very confident

Confident

Little confidence

No confidence

Question Title

* 4. GPP is characterized by which of the following?

Gradual appearance of intensely pruritic, dome-shaped papules

Sudden eruption of painful, pruritic, neutrophil-rich pustules

Fever and malaise followed a day or two later by pus-filled lesions

Rapid onset of widespread, scaly, fluid-and-blood-filled cysts

Question Title

* 5. Which of the following is the most common comorbidity of GPP?

Atopic dermatitis

Plaque psoriasis

Type 2 diabetes

von Zumbusch psoriasis

Question Title

* 6. Populations that are more frequently affected by GPP include which of the following?

Men and Asians

Men and Blacks

Women and Asians

Women and Blacks

Question Title

* 7. GPP is an autoimmune disorder caused mostly by mutations in which gene?

CARD14

IL17A

IL31RA

IL36RN

Question Title

* 8. IL-36 receptor antagonists improve or resolve symptoms and sequelae of GPP by binding to the IL-36 receptor, which prevents what?

IL-36 α, β, and γ isoforms from dimerizing the IL-1RAcP receptor

Downstream signaling of disease-specific proinflammatory cytokines

Activation of neutrophil-derived proteases that stimulate IL-36

Recruitment of self-reactive dendritic, B-, and T-cells into the skin

Question Title

* 9. In the Effisayil 1 trial of 53 patients with GPP, what percentage of patients taking spesolimab achieved the primary endpoint of GPPGA score of 0 or 1 (clear or almost clear skin) by week 1 vs 6% of those taking placebo?

67%

54%

35%

27%

Question Title

* 10. Andrea, a 42-year-old woman with a history of GPP, lives in fear of when her next flare might occur. She has been relying on oral corticosteroids to prevent flare and is afraid to go off them because she knows that systemic steroid withdrawal is a common trigger for flare. Which treatment might be best to prevent GPP flare?

Cyclosporine + anti-TNF-α

Anti-IL-17 biologic

Anti-IL-36 spesolimab

Anti-IL-36 imsidolimab

Question Title

* 11. An online survey of 66 people living with GPP in the United States found which of the following two activities were most severely affected by GPP flare?

Physical activity and intimacy

Important life events and socializing

Running errands and household chores

Question Title

* 12. Contact Information

Full Name

Email address

Phone number